27 results on '"Fabrizio Luciano"'
Search Results
2. Upcycling of PET from recycled food packaging trays via vitrimers chemistry
- Author
-
Fabrizio, Luciano, Arrigo, Rossella, Scrivani, Maria Teresa, Monti, Marco, and Fina, Alberto
- Published
- 2023
- Full Text
- View/download PDF
3. CCR Translation for this Article from Expression of Mutated IGHV3-23 Genes in Chronic Lymphocytic Leukemia Identifies a Disease Subset with Peculiar Clinical and Biological Features
- Author
-
Valter Gattei, Gianluca Gaidano, Giovanni Del Poeta, Dimitar G. Efremov, Roberto Marasca, Massimo Degan, Milena S. Nicoloso, Emanuele Zucca, Pietro Bulian, Francesca Maria Rossi, Antonella Zucchetto, Ilaria Cattarossi, Elisa Sozzi, Fabrizio Luciano, Maria Ilaria Del Principe, Davide Rossi, Luca Laurenti, Rossana Maffei, Francesco Bertoni, Daniela Marconi, Francesco Forconi, Daniela Capello, Dania Benedetti, Michele Dal-Bo, and Riccardo Bomben
- Abstract
CCR Translation for this Article from Expression of Mutated IGHV3-23 Genes in Chronic Lymphocytic Leukemia Identifies a Disease Subset with Peculiar Clinical and Biological Features
- Published
- 2023
4. Supplementary Data from Expression of Mutated IGHV3-23 Genes in Chronic Lymphocytic Leukemia Identifies a Disease Subset with Peculiar Clinical and Biological Features
- Author
-
Valter Gattei, Gianluca Gaidano, Giovanni Del Poeta, Dimitar G. Efremov, Roberto Marasca, Massimo Degan, Milena S. Nicoloso, Emanuele Zucca, Pietro Bulian, Francesca Maria Rossi, Antonella Zucchetto, Ilaria Cattarossi, Elisa Sozzi, Fabrizio Luciano, Maria Ilaria Del Principe, Davide Rossi, Luca Laurenti, Rossana Maffei, Francesco Bertoni, Daniela Marconi, Francesco Forconi, Daniela Capello, Dania Benedetti, Michele Dal-Bo, and Riccardo Bomben
- Abstract
Supplementary Data from Expression of Mutated IGHV3-23 Genes in Chronic Lymphocytic Leukemia Identifies a Disease Subset with Peculiar Clinical and Biological Features
- Published
- 2023
5. Data from Expression of Mutated IGHV3-23 Genes in Chronic Lymphocytic Leukemia Identifies a Disease Subset with Peculiar Clinical and Biological Features
- Author
-
Valter Gattei, Gianluca Gaidano, Giovanni Del Poeta, Dimitar G. Efremov, Roberto Marasca, Massimo Degan, Milena S. Nicoloso, Emanuele Zucca, Pietro Bulian, Francesca Maria Rossi, Antonella Zucchetto, Ilaria Cattarossi, Elisa Sozzi, Fabrizio Luciano, Maria Ilaria Del Principe, Davide Rossi, Luca Laurenti, Rossana Maffei, Francesco Bertoni, Daniela Marconi, Francesco Forconi, Daniela Capello, Dania Benedetti, Michele Dal-Bo, and Riccardo Bomben
- Abstract
Purpose: B-cell chronic lymphocytic leukemia (CLL) is a clinically heterogeneous disease whose outcome can be foreseen by investigating the mutational status of immunoglobulin heavy chain variable (IGHV) genes. Moreover, a different prognosis was reported for CLL expressing specific IGHV genes in the context or not of stereotyped B-cell receptors. Here we investigated novel associations between usage of specific IGHV genes and clinical features in CLL.Experimental Design: Among 1,426 CLL-specific IG-rearrangements, stereotyped B-cell receptor clusters never utilized the IGHV3-23 gene. Given this notion, this study was aimed at characterizing the IGHV3-23 gene in CLL, and identifying the properties of IGHV3-23–expressing CLL.Results: IGHV3-23 was the second most frequently used (134 of 1,426) and usually mutated (M; 109 of 134) IGHV gene in our CLL series. In the vast majority of M IGHV3-23 sequences, the configuration of the 13 amino acids involved in superantigen recognition was consistent with superantigen binding. Clinically, M IGHV3-23 CLL had shorter time-to-treatment than other M non–IGHV3-23 CLL, and multivariate analyses selected IGHV3-23 gene usage, Rai staging, and chromosomal abnormalities as independent prognosticators for M CLL. Compared with M non–IGHV3-23 CLL, the gene expression profile of M IGHV3-23 CLL was deprived in genes, including the growth/tumor suppressor genes PDCD4, TIA1, and RASSF5, whose downregulation is under control of miR-15a and miR-16-1. Accordingly, relatively higher levels of miR-15a and miR-16-1 were found in M IGHV3-23 compared with M non–IGHV3-23 CLL.Conclusions: Altogether, expression of the IGHV3-23 gene characterizes a CLL subset with distinct clinical and biological features. Clin Cancer Res; 16(2); 620–8
- Published
- 2023
6. Upcycling of PET from recycled food packaging trays via vitrimers chemistry
- Author
-
Fabrizio, Luciano, primary, Arrigo, Rossella, additional, Scrivani, Maria Teresa, additional, Monti, Marco, additional, and Fina, Alberto, additional
- Published
- 2022
- Full Text
- View/download PDF
7. CD69 is independently prognostic in chronic lymphocytic leukemia: a comprehensive clinical and biological profiling study
- Author
-
Fabrizio Luciano, Antonella Zucchetto, Giovanni Del Poeta, Adriano Venditti, Paolo de Fabritiis, Antonio Bruno, Pietro Bulian, Luca Maurillo, Annalisa Biagi, Sergio Amadori, Valter Gattei, Cristina Simotti, Francesco Buccisano, Francesca Rossi, Michele Dal Bo, Riccardo Bomben, Maria Ilaria Del Principe, Angela Coletta, and Benedetta Neri
- Subjects
Adult ,Antigens, Differentiation, T-Lymphocyte ,Male ,Oncology ,medicine.medical_specialty ,Chronic lymphocytic leukemia ,chemical and pharmacologic phenomena ,CD38 ,Cohort Studies ,Antibodies, Monoclonal, Murine-Derived ,Immunophenotyping ,Antigens, CD ,immune system diseases ,Internal medicine ,Biomarkers, Tumor ,medicine ,Humans ,Lectins, C-Type ,Progression-free survival ,Aged ,Aged, 80 and over ,business.industry ,CD23 ,hemic and immune systems ,Hematology ,Middle Aged ,Prognosis ,medicine.disease ,Leukemia, Lymphocytic, Chronic, B-Cell ,Fludarabine ,Leukemia ,Immunology ,Female ,Rituximab ,Original Articles and Brief Reports ,business ,Settore MED/15 - Malattie del Sangue ,Vidarabine ,medicine.drug - Abstract
Background CD69 is expressed in several hemopoietic cells and is an early activation marker in chronic lymphocytic leukemia. Chronic lymphocytic leukemia is a clinically heterogeneous disease which needs novel prognostic parameters which can be easily and efficiently managed. Design and Methods We investigated CD69 by flow cytometry in a series of 417 patients affected by chronic lymphocytic leukemia and compared this to other biological and clinical prognosticators. Results CD69 was associated with Rai stages ( P =0.00002), β2-microglobulin ( P =0.0005) and soluble CD23 ( P
- Published
- 2011
8. The genotype nucleophosmin mutated andFLT3-ITD negative is characterized by high bax/bcl-2 ratio and favourable outcome in acute myeloid leukaemia
- Author
-
Adriano Venditti, Maria Ilaria Del Principe, Roberto Stasi, Serena Zaza, Giovanni Capelli, Luca Maurillo, Fabrizio Luciano, Sergio Amadori, Francesco Buccisano, Francesco Lo Coco, Paola Panetta, Paolo de Fabritiis, Emanuele Ammatuna, Tiziana Ottone, Serena Lavorgna, and Giovanni Del Poeta
- Subjects
Myeloid ,Male ,medicine.medical_specialty ,NPM1 ,Acute ,Biology ,hemic and lymphatic diseases ,Internal medicine ,Genotype ,Biomarkers, Tumor ,medicine ,Humans ,Tumor Markers ,Prognosis ,Retrospective Studies ,bcl-2-Associated X Protein ,Middle Aged ,Mutation ,Proto-Oncogene Proteins c-bcl-2 ,Female ,Survival Analysis ,fms-Like Tyrosine Kinase 3 ,Nuclear Proteins ,Tumor Markers, Biological ,Leukemia, Myeloid, Acute ,Tandem Repeat Sequences ,Survival analysis ,Nucleophosmin ,Leukemia ,Hematology ,Cancer ,Biological ,medicine.disease ,body regions ,medicine.anatomical_structure ,embryonic structures ,Cancer research ,Settore MED/15 - Malattie del Sangue ,psychological phenomena and processes - Abstract
Nucleophosmin gene (NPM1) mutations characterize acute myeloid leukaemia (AML) with normal karyotype and frequently co-exist with FLT3 internal tandem duplications (ITD). We evaluated bcl-2, bax, NPM1 and FLT3-ITD in 222 AML patients. Bax/bcl-2 ratio >0.35 and NPM1 without FLT3-ITD were significantly associated (P = 0.0001). NPM1-mutated (mt)/FLT3-ITD negative patients showed a higher complete remission (CR) rate (90%, P = 0.0002) and a longer overall survival (OS, P = 0.00007). NPM1-mt/FLT3-ITD negative plus bax/bcl-2 > 0.35 subset showed a very high CR rate (96%), very long OS (P = 0.00005) and disease-free survival (P = 0.004). The favourable prognosis of NPM1-mt/FLT3-ITD negative patients might be explained by a higher bax/bcl-2 ratio.
- Published
- 2010
9. Deregulation of the Mitochondrial Apoptotic Machinery and Development of Molecular Targeted Drugs in Acute Myeloid Leukemia
- Author
-
G Del Poeta, Luca Maurillo, M. I. Del Principe, P. De Fabritiis, Fabrizio Luciano, Agostina Siniscalchi, S. Amadori, Roberto Stasi, Benedetta Neri, Francesco Buccisano, Adriano Venditti, and A Bruno
- Subjects
Myeloid ,Cancer Research ,Daunorubicin ,CD33 ,Drug Resistance ,Antineoplastic Agents ,Apoptosis ,Acute ,Biology ,hemic and lymphatic diseases ,Animals ,Humans ,Treatment Outcome ,Apoptosis Regulatory Proteins ,Mitochondria ,Drug Resistance, Neoplasm ,Leukemia, Myeloid, Acute ,Drug Design ,Signal Transduction ,Drug Discovery ,medicine ,Pharmacology ,Leukemia ,Oblimersen ,Myeloid leukemia ,medicine.disease ,medicine.anatomical_structure ,Oncology ,Immunology ,Cancer research ,Cytarabine ,Neoplasm ,Apoptosome ,Settore MED/15 - Malattie del Sangue ,medicine.drug - Abstract
Apoptosis plays a key role in the control of rapidly renewing tissues, such as the hematopoietic system and leukemia cells invariably have abnormalities in one or more apoptotic pathways, determining a survival advantage of these cells and the development of drug resistance. These defects are also frequently associated with a low rate of response to standard chemotherapy and with a poor survival in acute myeloid leukemia (AML). The major form of apoptosis proceeds through the mitochondrial pathway, with the mitochondrial outer membrane permeabilization, leading to the release of proteins normally found in the space between the inner and outer mitochondrial membranes (cytochrome C, AIF and others). Higher levels of anti-apoptosis proteins bcl-2, bcl-x(L), Mcl-1 block permeabilization of the membrane and are reported in AML patients presenting a poor outcome. On the contrary, activated pro-apoptotic bax or bad proteins allow this permeabilization and are correlated to a good prognosis in AML. Defects in the mitochondrial pathway induce multidrug-resistance and confer important prognostic information in AML. High ratios of bcl-2 to bax protein confer a poor prognosis with decreased rates of complete remission and overall survival. The prognostic information from the ratio of the proteins is greater than bcl-2 levels alone. Recently, we confirmed the impressive impact of the bax/bcl-2 ratio, determined by flow cytometry, on AML prognosis (complete remission and overall survival) in 255 AML patients. Bcl-2 down regulation might lower the apoptotic threshold of leukemic cells and, through this mechanism, favor response to chemotherapy. Phase II studies of oblimersen (antisense Bcl-2), cytarabine and daunorubicin or oblimersen plus gentuzumab, a cytotoxic antibody directed against CD33+ cells in relapsed AMLs, showed promising results. Defects in apoptosome proteins, such as APAF-1, are frequent in AML and treatment with 5-aza-2'-deoxycytidine, a specific inhibitor of DNA methylation, restored APAF-1 expression in leukemic cells. In conclusion, targeted therapies that are designed to induce apoptosis in leukemic cells, are the most promising anti-leukemia strategies. The elucidation of the apoptotic machinery and of its defects in AML lays the basis for developing new drugs able to trigger apoptosis and overcome therapy resistance.
- Published
- 2008
10. Bone quality and bone strength: benefits of the bone-forming approach
- Author
-
L. Frizzi, Francesca Gimigliano, Gioconda Di Pietro, Fabrizio Luciano, Giovanni Iolascon, Annarita Capaldo, Iolascon, Giovanni, Frizzi, L, Di Pietro, G, Capaldo, A, Luciano, F, and Gimigliano, Francesca
- Subjects
business.industry ,cortical bone ,Osteoporosis ,Mini-Review ,medicine.disease ,bone quality ,Resorption ,medicine.anatomical_structure ,Bone strength ,Strontium ranelate ,strontium ranelate ,Bone quality ,medicine ,Cortical bone ,Bone forming ,business ,Cancellous bone ,Biomedical engineering ,medicine.drug - Abstract
The ability of bone to resist fracture depends on the intrinsic properties of the materials that comprise the bone matrix mineralization, the amount of bone (i.e. mass), and the spatial distribution of the bone mass (i.e. microarchitecture). Antiresorptive agents may prevent the decay of cancellous bone and cortical thinning, with no improvement of bone microstructure, leading to a partial correction of the principal bone quality defect in osteoporosis, the disruption of trabecular microarchitecture. Anabolic agents promote bone formation at both trabecular and endocortical surfaces, resulting in an increase of cancellous bone volume and cortical thickness. The improvement of cortical bone strength may be limited by an increase in cortical porosity. strontium ranelate improves trabecular network and cortical thickness that will contribute to anti-fracture efficacy at both vertebral and non-vertebral sites. The results of clinical and experimental studies are consistent with the mode of action of strontium involving dissociation between bone formation and resorption leading to a stimulation both trabecular and cortical bone formation without increasing cortical porosity.
- Published
- 2014
11. 13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia
- Author
-
Anna Guarini, Ilaria Del Giudice, Robin Foà, Davide Rossi, Fabrizio Luciano, Gianluca Gaidano, Erika Tissino, Andrea Rinaldi, Francesco Di Raimondo, Marco Ladetto, Michele Dal Bo, Giovanni Del Poeta, Emanuele Cencini, Luca Laurenti, Gabriele Pozzato, Mauro Nanni, Alessandro Gozzetti, Giorgia Corradini, Valter Gattei, Pietro Bulian, Angela Coletta, Clara Deambrogi, Francesco Bertoni, Ivo Kwee, Roberto Marasca, Giuseppe A. Palumbo, Francesco Forconi, Francesca Rossi, Dal Bo, M, Rossi, Fm, Rossi, D, Deambrogi, C, Bertoni, F, Del Giudice, I, Palumbo, G, Nanni, M, Rinaldi, A, Kwee, I, Tissino, E, Corradini, G, Gozzetti, A, Cencini, E, Ladetto, M, Coletta, Am, Luciano, F, Bulian, P, Pozzato, Gabriele, Laurenti, L, Forconi, F, Di Raimondo, F, Marasca, R, Del Poeta, G, Gaidano, G, Foà, R, Guarini, A, and Gattei, V.
- Subjects
Cancer Research ,Chronic lymphocytic leukemia ,Chromosome Disorders ,Retinoblastoma Protein ,Cohort Studies ,hemic and lymphatic diseases ,genetics ,Pair 13 ,Chronic ,In Situ Hybridization, Fluorescence ,In Situ Hybridization ,Sequence Deletion ,chronic lymphocytic leukemia ,FISH analysis ,prognosis ,Leukemia ,medicine.diagnostic_test ,Retinoblastoma protein ,Prognosis ,Lymphocytic ,medicine.anatomical_structure ,RNA, Long Noncoding ,Chromosome Deletion, Chromosome Disorders ,genetics, Chromosomes ,Human ,genetics, Cohort Studies, Humans, In Situ Hybridization ,Fluorescence ,methods, Leukemia ,B-Cell ,genetics/pathology, Prognosis, Retinoblastoma Protein ,genetics, Sequence Deletion, Tumor Suppressor Proteins ,Chromosome Deletion ,Locus (genetics) ,In situ hybridization ,Biology ,Chromosomes ,methods ,Transferases ,fluorescence in situ hybridization ,miRNA ,microRNA ,medicine ,Humans ,B cell ,Chromosomes, Human, Pair 13 ,Tumor Suppressor Proteins ,genetics/pathology ,medicine.disease ,Molecular biology ,Leukemia, Lymphocytic, Chronic, B-Cell ,eye diseases ,biology.protein ,Settore MED/15 - Malattie del Sangue ,Fluorescence in situ hybridization - Abstract
Deletion at 13q14 is detected by fluorescence in situ hybridization (FISH) in about 50% of chronic lymphocytic leukemia (CLL). Although CLL with 13q deletion as the sole cytogenetic abnormality (del13q-only) usually have good prognosis, more aggressive clinical courses are documented for del13q-only CLL carrying higher percentages of 13q deleted nuclei. Moreover, deletion at 13q of different sizes have been described, whose prognostic significance is still unknown. In a multi-institutional cohort of 342 del13q-only cases and in a consecutive unselected cohort of 265 CLL, we investigated the prognostic significance of 13q deletion, using the 13q FISH probes locus-specific identifier (LSI)-D13S319 and LSI-RB1 that detect the DLEU2/MIR15A/MIR16-1 and RB1 loci, respectively. Results indicated that both percentage of deleted nuclei and presence of larger deletions involving the RB1 locus cooperated to refine the prognosis of del13q-only cases. In particular, CLL carrying
- Published
- 2011
12. 13q14 Chromosome Deletion Size and Number of Deleted Cells Influence Prognosis In Chronic Lymphocytic Leukemia
- Author
-
Giuseppe A. Palumbo, Valter Gattei, Robin Foà, Ilaria Del Giudice, Giovanni Del Poeta, Ivo Kwee, Roberto Marasca, Michele Dal Bo, Alessandro Gozzetti, Clara Deambrogi, Giorgia Corradini, Mauro Nanni, Gianluca Gaidano, Francesco Forconi, Erika Tissino, Anna Guarini, Angela Coletta, Francesco Bertoni, Davide Rossi, Rosaria Crupi, Francesco Di Raimondo, Andrea Rinaldi, Luca Laurenti, Francesca Rossi, Gabriele Pozzato, Fabrizio Luciano, and Marco Ladetto
- Subjects
medicine.medical_specialty ,Pathology ,Chronic lymphocytic leukemia ,Immunology ,Chromosome ,Context (language use) ,Karyotype ,Cell Biology ,Hematology ,Biology ,CD38 ,medicine.disease ,Biochemistry ,Gastroenterology ,Internal medicine ,Concomitant ,medicine ,IGHV@ ,Chromosome 12 - Abstract
Abstract 3578 Introduction: Chronic lymphocytic leukemia (CLL) patients bearing 13q14 deletion are known to experience a more favorable clinical course. Recent studies, focusing on patients with loss of 13q as the sole cytogenetic aberration at diagnosis (del13q-only cases), showed that the number of malignant cells carrying this genetic lesion correlates with a more aggressive clinical behavior. However, whether the size of the 13q deletion may also influence the clinical outcome remains to be elucidated. Patients and Methods: Probes for chromosome 13q (LSI-RB1, LSI-D13S319), 11q (LSI-ATM), 17p (LSI-p53) and chromosome 12 (CEP12) were utilized on nuclei collected at diagnosis from: i) a multi-institutional CLL cohort (342 del13q-only cases) and ii) a consecutive unselected single-institution cohort of 265 cases. RB1 deleted cases (delRB1) were defined as having at least 5% of deleted nuclei. Time to treatment (TTT) intervals, as well as Rai staging, IGHV mutational status, CD38 and ZAP70 expression, B2-microglobulin levels, all evaluated at diagnosis, were also available for all cases that entered the study. Genome wide DNA profile was performed in a pilot series of 90 CLL samples using Affymetrix GeneChip Human SNP6 arrays. Results: According to genome wide DNA analysis, delRB1 occurred in a proportion of del13q-only cases (36/90; 40%), always comprising the deleted region detected with the LSI-D13S319 probe (that covers the miR-15a/16-1 cluster and the DLEU2 gene) and characterized by a larger chromosome loss (median size 2.07 Mb vs. a median size of 0.86 Mb for the canonical del13S319). Maximally selected log-rank statistics identified the 70% of nuclei bearing del13S319 as the most appropriate cut-off value capable of separating del13q-only cases into two subgroups with different TTT distributions. Consistently, del13q-only cases with at least 70% of nuclei bearing del13S319 showed a significantly shorter TTT than del13q-only cases with less than 70% deleted nuclei (p=0.0001). Del13q-only cases were then divided in four subsets according to the percentage of nuclei bearing del13S319 with or without a concomitant delRB1: del13S319 70% (group 3), 64 cases; del13S319 >70% + delRB1 (group 4), 39 cases. The median TTT of group 1 (not reached) was significantly longer than the median TTT of group 2 (92 months, p=0.012), group 3 (68 months, p70% of cells (with or without delRB1, group C, 25 cases) or a normal karyotype (group D, 75 cases) had shorter median TTT intervals (ranging from 105 to 129 months, p Conclusion: In the context of del13q-only cases, different clinical outcomes were associated to the percentage of 13q14 deleted cells, as well as to the size of the 13q14 deletion, as detected by the LSI-RB1 probe. Moreover, the presence of delRB1 emerged as a feature capable of refining the prognostic assessment in the context of CLL cases with Disclosures: No relevant conflicts of interest to declare.
- Published
- 2010
13. Expression of mutated IGHV3-23 genes in chronic lymphocytic leukemia identifies a disease subset with peculiar clinical and biological features
- Author
-
Michele Dal-Bo, Pietro Bulian, Daniela Capello, Ilaria Cattarossi, Antonella Zucchetto, Roberto Marasca, Fabrizio Luciano, Riccardo Bomben, Maria Ilaria Del Principe, Emanuele Zucca, Francesca Rossi, Gianluca Gaidano, Daniela Marconi, Francesco Forconi, Valter Gattei, Francesco Bertoni, Dimitar G. Efremov, Milena S. Nicoloso, Giovanni Del Poeta, Rossana Maffei, Luca Laurenti, Elisa Sozzi, Dania Benedetti, Massimo Degan, and Davide Rossi
- Subjects
Cancer Research ,Chronic lymphocytic leukemia ,Cohort Studies ,BCL9 ,immune system diseases ,hemic and lymphatic diseases ,Diagnosis ,80 and over ,genetics ,Chronic ,Aged, 80 and over ,Regulation of gene expression ,Leukemic ,Gene Rearrangement ,Leukemia ,Gene Expression Regulation, Leukemic ,Middle Aged ,Prognosis ,Lymphocytic ,Oncology ,CLL IGHV3-23 microRNAs prognosis ,IGHV@ ,Adult ,Genes, Immunoglobulin Heavy Chain ,Mutant Proteins ,Diagnosis, Differential ,MicroRNAs ,Neoplasm Staging ,Humans ,Aged ,Gene Expression Profiling ,Leukemia, Lymphocytic, Chronic, B-Cell ,Immunoglobulin Heavy Chain ,Context (language use) ,Biology ,Adult, Aged, Aged ,80 and over, Cohort Studies, Diagnosis ,Differential, Gene Expression Profiling, Gene Expression Regulation ,Leukemic, Gene Rearrangement ,physiology, Genes ,genetics, Humans, Leukemia ,B-Cell ,classification/diagnosis/genetics/pathology, MicroRNAs ,genetics, Middle Aged, Mutant Proteins ,genetics, Neoplasm Staging, Prognosis ,medicine ,Gene ,medicine.disease ,Gene expression profiling ,classification/diagnosis/genetics/pathology ,Gene Expression Regulation ,Genes ,Immunology ,Differential ,physiology ,Settore MED/15 - Malattie del Sangue - Abstract
Purpose: B-cell chronic lymphocytic leukemia (CLL) is a clinically heterogeneous disease whose outcome can be foreseen by investigating the mutational status of immunoglobulin heavy chain variable (IGHV) genes. Moreover, a different prognosis was reported for CLL expressing specific IGHV genes in the context or not of stereotyped B-cell receptors. Here we investigated novel associations between usage of specific IGHV genes and clinical features in CLL. Experimental Design: Among 1,426 CLL-specific IG-rearrangements, stereotyped B-cell receptor clusters never utilized the IGHV3-23 gene. Given this notion, this study was aimed at characterizing the IGHV3-23 gene in CLL, and identifying the properties of IGHV3-23–expressing CLL. Results: IGHV3-23 was the second most frequently used (134 of 1,426) and usually mutated (M; 109 of 134) IGHV gene in our CLL series. In the vast majority of M IGHV3-23 sequences, the configuration of the 13 amino acids involved in superantigen recognition was consistent with superantigen binding. Clinically, M IGHV3-23 CLL had shorter time-to-treatment than other M non–IGHV3-23 CLL, and multivariate analyses selected IGHV3-23 gene usage, Rai staging, and chromosomal abnormalities as independent prognosticators for M CLL. Compared with M non–IGHV3-23 CLL, the gene expression profile of M IGHV3-23 CLL was deprived in genes, including the growth/tumor suppressor genes PDCD4, TIA1, and RASSF5, whose downregulation is under control of miR-15a and miR-16-1. Accordingly, relatively higher levels of miR-15a and miR-16-1 were found in M IGHV3-23 compared with M non–IGHV3-23 CLL. Conclusions: Altogether, expression of the IGHV3-23 gene characterizes a CLL subset with distinct clinical and biological features. Clin Cancer Res; 16(2); 620–8
- Published
- 2010
14. Prognostic impact of ZAP-70 expression in chronic lymphocytic leukemia: mean fluorescence intensity T/B ratio versus percentage of positive cells
- Author
-
Maria Irno Consalvo, Dania Benedetti, Pietro Bulian, Antonella Zucchetto, Giovanni Del Poeta, Davide Rossi, Riccardo Bomben, Valter Gattei, Fabrizio Luciano, Marco Fangazio, Francesca Rossi, Maria Ilaria Del Principe, Massimo Degan, Gianluca Gaidano, and Michele Dal Bo
- Subjects
Male ,Chronic lymphocytic leukemia ,T-Lymphocytes ,lcsh:Medicine ,Kaplan-Meier Estimate ,80 and over ,Medicine ,Chronic ,Tumor Markers ,Aged, 80 and over ,Medicine(all) ,B-Lymphocytes ,Leukemia ,ZAP-70 Protein-Tyrosine Kinase ,medicine.diagnostic_test ,Mean fluorescence intensity ,hemic and immune systems ,General Medicine ,Middle Aged ,Prognosis ,Flow Cytometry ,Lymphocytic ,Reproducibility of Results ,Humans ,Aged ,Multivariate Analysis ,Leukemia, Lymphocytic, Chronic, B-Cell ,Adult ,Immunoglobulin Heavy Chains ,Tumor Markers, Biological ,Mutation ,Lymphocyte Subsets ,Female ,Lymphocyte subsets ,chemical and pharmacologic phenomena ,General Biochemistry, Genetics and Molecular Biology ,Flow cytometry ,Biomarkers, Tumor ,business.industry ,Biochemistry, Genetics and Molecular Biology(all) ,Research ,lcsh:R ,B-Cell ,medicine.disease ,Biological ,Immunology ,Cancer research ,Immunoglobulin heavy chain ,business ,Settore MED/15 - Malattie del Sangue - Abstract
Background ZAP-70 is an independent negative prognostic marker in chronic lymphocytic leukemia (CLL). Usually, its expression is investigated by flow cytometric protocols in which the percentage of ZAP-70 positive CLL cells is determined in respect to isotypic control (ISO-method) or residual ZAP-70 positive T cells (T-method). These methods, however, beside suffering of an inherent subjectivity in their application, may give discordant results in some cases. The aim of this study was to assess the prognostic significance of these methods in comparison with another in which ZAP-70 expression was evaluated as a Mean-Fluorescence-Intensity Ratio between gated T and CLL cells (T/B Ratio-method). Methods Cytometric files relative to ZAP-70 determination according to the three readouts were retrospectively reviewed on a cohort of 173 patients (test set), all with complete clinical and biological prognostic assessment and time-to-treatment (TTT) available. Findings were then validated in an independent cohort of 341 cases from a different institution (validation set). Results The optimal prognostic cut-offs for ZAP-70 expression were selected at 11% (ISO-method) or 20% of positive cells (T-method), as well as at 3.0 (T/B Ratio-method) in the test set; these cut-offs yielded 66, 60 and 73 ZAP-70+ cases, respectively. Univariate analyses resulted in a better separation of ZAP-70+ vs. ZAP-70- CLL patients utilizing the T/B Ratio, compared to T- or ISO-methods. In multivariate analyses which included the major clinical and biological prognostic markers for CLL, the prognostic impact of ZAP-70 appeared stronger when the T/B-Ratio method was applied. These findings were confirmed in the validation set, in which ZAP-70 expression, evaluated by the T- (cut-off = 20%) or T/B Ratio- (cut-off = 3.0) methods, yielded 180 or 127 ZAP-70+ cases, respectively. ZAP-70+ patients according to the T/B Ratio-method had shorter TTT, both if compared to ZAP-70- CLL, and to cases classified ZAP-70+ by the T-method only. Conclusions We suggest to evaluate ZAP-70 expression in routine settings using the T/B Ratio-method, given the operator and laboratory independent feature of this approach. We propose the 3.0 T/B Ratio value as optimal cut-off to discriminate ZAP-70+ (T/B Ratio less than 3.0) from ZAP-70- (T/B Ratio more/equal than 3.0) cases.
- Published
- 2010
15. Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia
- Author
-
Luca Maurillo, Michele Dal-Bo, Francesco Buccisano, Maria Ilaria Del Principe, Sergio Amadori, Giovanni Del Poeta, Francesca Rossi, Valter Gattei, Pietro Bulian, Massimo Degan, Antonella Zucchetto, Riccardo Bomben, and Fabrizio Luciano
- Subjects
Adult ,Male ,medicine.medical_specialty ,Chronic lymphocytic leukemia ,Integrin alpha4 ,Immunology ,CD38 ,Biochemistry ,Disease-Free Survival ,Predictive Value of Tests ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Biomarkers, Tumor ,Humans ,Aged ,Retrospective Studies ,Aged, 80 and over ,Hematology ,biology ,business.industry ,Gene Expression Regulation, Leukemic ,CD23 ,Cancer ,Cell Biology ,Middle Aged ,medicine.disease ,Leukemia, Lymphocytic, Chronic, B-Cell ,Neoplasm Proteins ,Survival Rate ,Phenotype ,Mutation ,biology.protein ,Cancer research ,Female ,Antibody ,business ,IGHV@ ,Settore MED/15 - Malattie del Sangue ,Progressive disease - Abstract
CD49d/α4-integrin is variably expressed in chronic lymphocytic leukemia (CLL). We evaluated its relevance as independent prognosticator for overall survival and time to treatment (TTT) in a series of 303 (232 for TTT) CLLs, in comparison with other biologic or clinical prognosticators (CD38, ZAP-70, immunoglobulin variable heavy chain (IGHV) gene status, cytogenetic abnormalities, soluble CD23, β2-microglobulin, Rai staging). Flow cytometric detection of CD49d was stable and reproducible, and the chosen cut-off (30% CLL cells) easily discriminated CD49dlow from CD49dhigh cases. CD49d, whose expression was strongly associated with that of CD38 (P < .001) and ZAP-70 (P < .001), or with IGHV mutations (P < .001), was independent prognosticator for overall survival along with IGHV mutational status (CD49d hazard ratio, HRCD49d = 3.52, P = .02; HRIGHV = 6.53, P < .001) or, if this parameter was omitted, with ZAP-70 (HRCD49d = 3.72, P = .002; HRZAP-70 = 3.32, P = .009). CD49d was also a prognosticator for TTT (HR = 1.74, P = .007) and refined the impact of all the other factors. Notably, a CD49dhigh phenotype, although not changing the outcome of good prognosis (ZAP-70low, mutated IGHV) CLL, was necessary to correctly prognosticate the shorter TTT of ZAP-70high (HR = 3.12; P = .023) or unmutated IGHV (HR = 2.95; P = .002) cases. These findings support the introduction of CD49d detection in routine prognostic assessment of CLL patients, and suggest both pathogenetic and therapeutic implications for CD49d expression in CLL.
- Published
- 2008
16. Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia
- Author
-
Giovanni Del Poeta, Fabrizio Luciano, Giovanni Capelli, Luca Maurillo, Francesco Buccisano, Sergio Amadori, Alessio Perrotti, Maria Ilaria Del Principe, Paolo de Fabritiis, Massimo Degan, Valter Gattei, and Adriano Venditti
- Subjects
Adult ,Cancer Research ,medicine.medical_specialty ,Neoplasm, Residual ,Chronic lymphocytic leukemia ,Immunoglobulin Variable Region ,Phases of clinical research ,Gastroenterology ,Disease-Free Survival ,Drug Administration Schedule ,Immunophenotyping ,Antibodies, Monoclonal, Murine-Derived ,Maintenance therapy ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Humans ,Survival analysis ,Aged ,business.industry ,Antibodies, Monoclonal ,Middle Aged ,Flow Cytometry ,medicine.disease ,Leukemia, Lymphocytic, Chronic, B-Cell ,Survival Analysis ,Minimal residual disease ,Surgery ,Fludarabine ,Leukemia ,Oncology ,Rituximab ,Immunoglobulin Heavy Chains ,business ,Settore MED/15 - Malattie del Sangue ,medicine.drug - Abstract
BACKGROUND. Rituximab in sequential combination with fludarabine (Flu) allowed patients with B-cell chronic lymphocytic leukemia (B-CLL) to achieve higher remission rates and longer response duration. Based on their recent experience in indolent non-Hodgkin lymphomas, in this study, the authors attempted to demonstrate whether consolidation/maintenance therapy with rituximab could prolong the response duration in this patient population. METHODS. This Phase II study was based on a consolidation/maintenance therapy with rituximab for patients in complete remission (CR) or partial remission (PR) who were positive for minimal residual disease (MRD), as determined by flow cytometry. Seventy-five symptomatic, untreated patients with B-CLL received 6 monthly cycles of Flu (25 mg/m2 for 5 days) followed by 4 weekly doses of rituximab (375 mg/m2). Then, 28 patients who were positive for MRD were consolidated with 4 monthly cycles of rituximab (375 mg/m2) followed by 12 monthly low doses of rituximab (150 mg/m2). RESULTS. Based on National Cancer Institute criteria, 61 of 75 patients (81%) achieved a CR, 10 of 75 patients (13%) had a PR, and 4 of 75 patients (5%) had either no response or disease progression. MRD-positive patients in CR or PR who received consolidation therapy (n = 28 patients) had a significantly longer response duration (87% vs 32% at 5 years; P = .001) compared with a subset of patients who did not receive consolidation therapy (n = 18 patients). All patients experienced a long progression-free survival from the end of induction treatment (73% at 5 years). It was noteworthy that, within the subset of ZAP-70-positive patients, MRD-positive, consolidated patients (n = 12 patients) had a significantly longer response duration (69% vs 0% at 2.6 years; P = .007) compared with MRD-positive, unconsolidated patients (n = 11 patients). CONCLUSIONS. The addition of a consolidation and maintenance therapy withrituximab prolonged response duration significantly in patients with MRD-positive B-CLL. Cancer 2008. © 2007 American Cancer Society.
- Published
- 2008
17. Clinical Monoclonal B Cell Lymphocytosis Is a Strong Favorable Prognosticator Independent From Biological and Clinical Parameters
- Author
-
Pietro Bulian, Pasquale Niscola, Maria Ilaria Del Principe, Francesco Buccisano, Adriano Venditti, Valter Gattei, Antonella Zucchetto, Sergio Amadori, Alessio Perrotti, Fabrizio Luciano, Paolo de Fabritiis, Giovanni Del Poeta, Annalisa Biagi, and Luca Maurillo
- Subjects
Pathology ,medicine.medical_specialty ,Lymphocytosis ,business.industry ,Immunology ,Cell Biology ,Hematology ,medicine.disease ,Biochemistry ,Asymptomatic ,hemic and lymphatic diseases ,Monoclonal ,medicine ,Monoclonal B-cell lymphocytosis ,medicine.symptom ,business - Abstract
Abstract 3887 Monoclonal B-cell lymphocytosis (MBL) is an asymptomatic monoclonal expansion of Disclosures: No relevant conflicts of interest to declare.
- Published
- 2011
18. Normal Fish Cytogenetics and 13q Deletions Unveil Marked Biological and Clinical Heterogeneity In Chronic Lymphocytic Leukemia
- Author
-
Pasquale Niscola, Maria Christina Cox, Paolo de Fabritiis, Maria Antonietta Irno Consalvo, Francesco Buccisano, Sergio Amadori, Alessio Perrotti, Luca Maurillo, Giovanni Del Poeta, Adriano Venditti, Maria Ilaria Del Principe, Valter Gattei, Fabrizio Luciano, Angela Coletta, Annalisa Biagi, Antonella Zucchetto, Cristina Simotti, and Francesca Rossi
- Subjects
medicine.medical_specialty ,Pathology ,medicine.diagnostic_test ,Surrogate endpoint ,Chronic lymphocytic leukemia ,Hybridization probe ,Immunology ,Cytogenetics ,Chromosome ,Cell Biology ,Hematology ,In situ hybridization ,Biology ,medicine.disease ,Biochemistry ,Flow cytometry ,medicine ,Abnormality - Abstract
Abstract 2692 Cytogenetic aberrations are considered major prognostic indicators for predicting the survival of chronic lymphocytic leukemia (CLL) patients (pts) [Dohner et al, 2000]. Given the difficulties in obtaining abnormal metaphases in CLL, fluorescent in situ hybridization (FISH) with specific probes is generally used to detect the most frequent abnormalities. Interphase FISH (I-FISH) is a rapid and sensitive technique for analysis of chromosome aberrations in CLL, but the limited number of DNA probes available to screen B-CLL results in a high number of cases presenting normal cytogenetics. Moreover, deletion 13q14 on FISH analysis which is the most common cytogenetic abnormality in CLL is a favourable prognostic biomarker when detected as a sole abnormality, but a higher percentage of 13q- nuclei was found to be associated with significantly shorter time to treatment (P Disclosures: No relevant conflicts of interest to declare.
- Published
- 2010
19. Clinical Significance of CD69 Expression In Chronic Lymphocytic Leukemia
- Author
-
Chiara Sarlo, Giovanni Del Poeta, Adriano Venditti, Valter Gattei, Annalisa Biagi, Licia Ottaviani, Sergio Amadori, Alessio Perrotti, Paolo de Fabritiis, Cristina Simotti, Maria Ilaria Del Principe, Pietro Bulian, Laura Giannì, Antonella Zucchetto, Francesco Buccisano, Luca Maurillo, and Fabrizio Luciano
- Subjects
Oncology ,Univariate analysis ,medicine.medical_specialty ,Beta-2 microglobulin ,Surrogate endpoint ,Chronic lymphocytic leukemia ,Immunology ,Cell Biology ,Hematology ,Biology ,medicine.disease ,Biochemistry ,Internal medicine ,medicine ,Doubling time ,Clinical significance ,Progression-free survival ,Stage (cooking) - Abstract
Abstract 3574 Chronic lymphocytic leukemia (B-CLL) is a very heterogeneous disease with some patients experiencing rapid disease progression and others living for years without requiring treatment and therefore it is mandatory to find new prognostic markers. CD69 overexpression which resembles B cells at an earlier and greater state of activation (Damle, 2002 and 2007) and induces increased proliferation and survival of leukemic B-lymphocytes, may reflect an aggressive and progressive clinical outcome. The primary endpoints of our research were: 1) to determine progression free survival (PFS) and overall survival (OS) upon CD69 in univariate analysis; 2) to correlate CD69 with other clinical or biological prognostic factors such as age, Rai stages, lymphocyte doubling time, beta-2 microglobulin, CD38, CD49d, ZAP-70, cytogenetics by FISH and IgVH status and finally, 3) to confirm CD69 as an independent prognostic factor. We investigated 417 patients (pts), median age 66 years (range 33–89), 239 males and 178 females. With regard to modified Rai stages, 127 pts had a low stage, 272 an intermediate stage and 18 a high stage. CD69 was determined by multicolor flow cytometry, fixing the cut-off value at 30%. CD69+ pts were 111/417 (26.6%). CD69 12 months (260/337; P=0.0006), beta-2 microglobulin or Disclosures: No relevant conflicts of interest to declare.
- Published
- 2010
20. The Amount of Mitochondrial Apoptosis Exerts Prognostic Impact on Normal Karyotype Acute Myeloid Leukemia
- Author
-
Luca Maurillo, Adriano Venditti, Licia Ottaviani, Giovanni Del Poeta, Paolo de Fabritiis, Francesco Buccisano, Fabrizio Luciano, Daniela Piccioni, Maria Irno Consalvo, Francesco Lo Coco, Sergio Amadori, Antonio Bruno, Emanuele Ammatuna, Maria Ilaria Del Principe, Benedetta Neri, and Valter Gattei
- Subjects
medicine.medical_specialty ,Bortezomib ,Immunology ,Cytogenetics ,CD34 ,Myeloid leukemia ,Cell Biology ,Hematology ,Biology ,Biochemistry ,Gastroenterology ,Chemotherapy regimen ,medicine.anatomical_structure ,Apoptosis ,Internal medicine ,White blood cell ,medicine ,Inner mitochondrial membrane ,medicine.drug - Abstract
The unbalance between anti-apoptotic (bcl-2) and pro-apoptotic mitochondrial proteins (bax) represents a critical mechanism explaining the high rate of resistance and treatment failure in acute myeloid leukemia (AML) (Del Poeta, 2003). Moreover, the availability of novel and effective pro-apoptotic compounds such as bortezomib (Attar, 2008) and gemtuzumab (Del Poeta, 2008) moved us to widely investigate the impact of mitochondrial proteins such as bcl-2, bax and 7A6 on AML prognosis. 7A6 antigen has been found to be exposed on the mitochondrial membrane during the early stages of apoptosis and is recognized by monoclonal antibody APO2.7. For this purpose, a large series of 420 non M3 AML patients (pts), median age 63 years, treated with intensive chemotherapy regimens, were tested. The aims of our research were: to correlate bax/bcl-2 and APO2.7/bcl-2 ratios, as measures of mitochondrial apoptosis, with other well-known prognostic factors such as age, cytogenetics, FLT3-ITD, P-glycoprotein; to evaluate whether mitochondrial apoptosis was able to dissect normal karyotype AML with regard to prognosis, and finally to confirm that mitochondrial apoptosis is an independent prognostic factor. Bcl-2, bax and 7A6 proteins were assessed by multicolor flow cytometry and bax/bcl-2 or APO2.7/bcl-2 ratios were obtained by dividing mean fluorescence intensity (MFI) of bax/MFI bcl-2 or MFI of APO2.7/MFI bcl-2. The thresholds of positivity were set at the median values >0.35 and >0.60, respectively. Fifty-nine percent of pts were bax/bcl-2 positive and 50% were APO2.7/bcl-2 positive. There were strict correlations between higher bax/bcl-2 or higher APO2.7/bcl-2 and FAB M2 or M4/M5 AML subgroups (p0.35 or APO2.7/bcl-2>0.60 and CD34 negativity (p
- Published
- 2008
21. Nucleophosmin Gene Mutations Exhibit High Spontaneous Apoptosis and Favorable Prognosis in Acute Myeloid Leukemia
- Author
-
Serena Zaza, Luca Maurillo, Fabrizio Luciano, Gianfranco Catalano, Sergio Amadori, Giovanni Del Poeta, Maria Ilaria Del Principe, Paolo de Fabritiis, Serena Lavorgna, Francesco Buccisano, Emanuele Ammatuna, Francesco Lo Coco, Tiziana Ottone, and Adriano Venditti
- Subjects
Nucleophosmin ,NPM1 ,medicine.diagnostic_test ,business.industry ,Immunology ,CD34 ,Myeloid leukemia ,Adult Acute Myeloid Leukemia ,Cell Biology ,Hematology ,Gene mutation ,Biochemistry ,Flow cytometry ,body regions ,Apoptosis ,hemic and lymphatic diseases ,Cancer research ,Medicine ,business ,psychological phenomena and processes - Abstract
Nucleophosmin gene mutations (NPM1-Mt) are the hallmark of a large adult acute myeloid leukemia (AML) subgroup with normal karyotype and interact with p53 and its regulatory molecules (Arf, Hdm2/Mdm2), thus lowering cell proliferation and increasing apoptosis (Falini, 2007). Moreover, AML pts show co-existing NPM1-Mt and internal tandem duplications of FLT3 (FLT3-ITD) which increase potential for cell proliferation. Furthermore, genes and proteins involved in apoptosis, such as bcl-2 and bax, have been demonstrated to be relevant in response to treatment and outcome (Del Poeta, 2003). Therefore, we analysed NPM1-Mt, FLT3-ITD and apoptosis proteins (bcl-2 and bax) in 222 pts, affected by de novo non-M3 AML, median age 60 years, treated with intensive chemotherapy regimens according to GIMEMA-EORTC protocols. The aims of our study were: to correlate NPM1-Mt or FLT3-ITD with bax/bcl-2 ratio levels, as a measure of spontaneous apoptosis; to assess the independent prognostic significance of NPM1-Mt and FLT3-ITD. Bcl-2 and bax proteins were determined by multicolor flow cytometry and bax/bcl-2 ratio was obtained by dividing mean fluorescence intensity (MFI) of bax/MFI bcl-2. The threshold of positivity was set at the median value >0.35 (range 0.01–9.1). NPM1 mutations and FLT3-ITD were detected by multiplex PCR and capillary gel electrophoresis. One hundred-twenty-one/222 (54.5%) pts were bax/bcl-2 ratio positive, 54/222 (24.3%) were NPM1-Mt and 52/222 (23.4%) presented FLT3-ITD; 17/222 (7.6%) pts carried both FLT3-ITD and NPM1-Mt. There was a strong correlation between higher WBC counts (>100x109/L) and FLT3-ITD (P0.35) and NPM1-Mt without FLT3-ITD were significantly associated (30/37; P=0.0001), demonstrating that NPM1-Mt alone express high amount of spontaneous apoptosis. Moreover, NPM1-Mt cases were significantly related to FAB M4 or M5 AML (P=0.03). A normal karyotype was found in 37/45 (82%) NPM1-Mt pts (P=0.00001) and almost all NPM1-Mt cases were CD34 negative (47/54; P
- Published
- 2007
22. High CD69 Protein Expression Predicts a Poor Prognosis in B-Cell Chronic Lymphocytic Leukemia (B-CLL)
- Author
-
Maria Ilaria Del Principe, Angela Coletta, Gianfranco Catalano, Paolo de Fabritiis, Pasquale Niscola, Francesco Buccisano, Giovanni Del Poeta, Adriano Venditti, Luca Maurillo, Laura Giannì, Fabrizio Luciano, Sergio Amadori, Antonella Zucchetto, and Valter Gattei
- Subjects
medicine.medical_specialty ,Beta-2 microglobulin ,Lymphocyte ,Chronic lymphocytic leukemia ,Immunology ,CD23 ,Cell Biology ,Hematology ,CD38 ,Biology ,medicine.disease ,Biochemistry ,Gastroenterology ,medicine.anatomical_structure ,Internal medicine ,medicine ,Doubling time ,IL-2 receptor ,Progression-free survival - Abstract
CD69 membrane protein is expressed early in the activation of lymphoid cells and is inducible by B-cells through cross-linking of surface immunoglobulins. Moreover, B-CLL cells exhibit features of activated and of antigen-experienced B lymphocytes overexpressing activation markers such as CD23, CD25, CD69 and CD71 (Damle, 2002). Furthermore, we have demonstrated that ZAP-70+ CLL subgroup shows a rapid disease progression and an inferior overall survival (Del Principe, 2006). The generation of antimurine CD69 monoclonal antibodies able to induce down-modulation or partial depletion of CD69+ cells (Sancho, 2006), prompted us to evaluate the real impact of CD69 expression on B-CLL prognosis. The primary aims of our study were: to determine progression-free survival (PFS) and overall survival (OS) upon CD69 expression; whether CD69 could predict varied outcome within ZAP-70+ and ZAP-70 negative subgroups; and finally whether CD69 was an independent prognostic factor. Therefore, we investigated 247 pts, median age 65 years, 131 males and 116 females. With regard to modified Rai stages, 69 pts had a low stage, 167 an intermediate stage and 11 a high stage. CD69 was determined by multicolor flow cytometry fixing a cut-off value of 30%. CD69+ B-CLL pts were 73/247 (30%). CD69 >30% was significantly associated with an intermediate/high Rai stage (p=0.001), lymphocyte doubling time (LDT) 2.2 mg/dl (p=0.002). Lower CD69 expression and IgVH mutated status (>2%) were significantly correlated (73/92; p=0.0003). Furthermore, we found significant associations between lower CD69 and lower CD38 (137/184; p=0.02) or lower ZAP-70 (110/144; p=0.01). Lower levels of soluble CD23 (sCD23) were strongly associated with lower CD69 (127/158; p Figure Figure
- Published
- 2007
23. Consolidation and Maintenance Immunotherapy with Rituximab Improve Progression Free Survival within ZAP-70 Positive Chronic Lymphocytic Leukemia (CLL)
- Author
-
Luca Maurillo, Giovanni Del Poeta, Antonella Zucchetto, Adriano Venditti, Maria Cantonetti, Francesco Buccisano, Maria Ilaria Del Principe, Valter Gattei, Paolo de Fabritiis, Fabrizio Luciano, Sergio Amadori, G Suppo, and Rita Marini
- Subjects
medicine.medical_specialty ,Chemotherapy ,business.industry ,medicine.medical_treatment ,Chronic lymphocytic leukemia ,Immunology ,Phases of clinical research ,Cell Biology ,Hematology ,Neutropenia ,medicine.disease ,Biochemistry ,Gastroenterology ,Surgery ,Fludarabine ,Maintenance therapy ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Rituximab ,Progression-free survival ,business ,medicine.drug - Abstract
Clinical studies of monoclonal antibodies combined with chemotherapy have attained more complete responses and longer duration of responses in CLL because this approach reduces disease burden to levels detectable only by immunological or molecular methods. Recent literature data indicate that VH genes, CD38, ZAP-70 protein, and cytogenetic status have a major impact on CLL prognosis. We performed a phase II study that added rituximab sequentially to fludarabine (Flu) as initial therapy for symptomatic, untreated CLL in order to evaluate both the clinical response and outcome. Remission status was also assessed by a multiparametric flow cytometric method based on the detection of CD19+CD5+CD79b− residual B-CLL lymphocytes. VH mutational status, CD38 and cytogenetics were obtained in all pts before treatment. ZAP-70 protein was performed by flow cytometry using an anti-ZAP-70 Alexa Fluor 488 conjugated antibody. Seventy-five CLL pts, median age 60 years, received six monthly courses of Flu (25 mg/m2 for 5 days) and four weekly doses of rituximab (375 mg/m2) starting on an average of thirty days after completion of Flu therapy. According to modified Rai stages, 6 pts had a low stage, 66 an intermediate stage and 3 a high stage. Based on NCI criteria, 61/75 (81%) pts achieved a complete remission (CR), 10/75 (13%) a partial remission (PR) and 4/75 (5%) no response. Three pts presented grade 3 (WHO) infective lung toxicity and 1 patient acute fatal B hepatitis. Hematologic toxicity included neutropenia (grade 3 and/or 4 in 38 pts) and thrombocytopenia (grade 3 and/or 4 in 4 pts). Twenty eight pts, either with CD5+CD19+CD79b− (MRD) bone marrow (BM) cells >1% (n=17 pts) or with CD19+CD5+CD79b− (MRD) peripheral blood lymphocytes (PBL) >1000/microl (n=11 pts) within six months after completion of the induction treatment, underwent consolidation/maintenance therapy with four monthly cycles of rituximab at 375 mg/m2 followed by twelve monthly doses of rituximab at 150 mg/m2. The median follow-up duration was 37 months. Noteworthy, all pts experienced a long progression-free survival (PFS) from treatment (67% at 5 years). Nevertheless, CLL pts that underwent consolidation therapy (n=28) showed a significant longer duration of response (75% vs 27% at 5 years, P=0.002) in comparison with the subset of not consolidated and BM or PBL MRD positive (n=18) CLL pts. Interestingly, BM and PBL MRD negative pts (n=26) showed a duration of response similar to that of the consolidated pts. Moreover, a significant shorter PFS was observed within CD38+ pts (29% vs 79% at 5 years, P=0.005), unmutated pts (0% vs 92% at 2 years, P=0.001), ZAP-70+ pts (29% vs 92% at 5 years; P=0.00003) and within the “poor risk” [trisomy 12 or del 11q or del 17p] cytogenetic subset (0% vs 79% at 2 years, P=0.03). Interestingly, within the ZAP-70+ subset (n=35), the consolidated pts (n=12) showed a longer duration of response (68% vs 0% at 2.6 years, P=0.007) in comparison with the unconsolidated pts (n=11). Therefore, the addition of a consolidation/maintenance therapy with rituximab prolongs significantly the duration of response allowing a better outcome. Moreover, rituximab improves significantly PFS of pts notoriously at worse prognosis, such as ZAP-70+ B-CLL.
- Published
- 2006
24. High CD49d protein expression predicts short overall survival and early progression in chronic lymphocytic leukemia patients
- Author
-
Maria Ilaria Del-Principe, Francesco Buccisano, Valter Gattei, Massimo Degan, Sergio Amadori, Antonella Zucchetto, Luca Maurillo, Michele Dal-Bo, Francesca Rossi, Giovanni Del-Poeta, Fabrizio Luciano, Riccardo Bomben, and Pietro Bulian
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,Chronic lymphocytic leukemia ,Multiple sclerosis ,Immunology ,Cell Biology ,Hematology ,Disease ,CD38 ,medicine.disease ,Biochemistry ,Natalizumab ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Stage (cooking) ,CD5 ,IGHV@ ,business ,medicine.drug - Abstract
B-cell chronic lymphocytic leukemia (CLL) is a heterogeneous disease with highly variable clinical courses which can be at least in part foreseen by investigating the expression of known prognosticators, including the IGHV gene mutational status or CD38/ZAP-70 expression. By analysing the coordinated expression of several surface antigens in a series of CLL with known clinical courses, we identified the simultaneous over-expression of CD38 and CD49d as part of the signature characterizing the subgroup with the worst outcome. The aim of the present study was to investigate the relationship between CD49d and other well-established biologic prognosticators (CD38 and ZAP-70 expression, IGHV gene mutational status), or markers of tumor burden (Rai clinical stage, beta2-M, sCD23), and to define the independent prognostic impact of CD49d in predicting overall survival (OS) and disease progression (evaluated as time-to-treatment, TTT) in CLL patients. The study includes samples from 303 patients affected by CLL according to the current diagnostic criteria (median age: 63.5 years, range 32–97). The entire cohort of patients was utilized to investigate the impact of CD49d and other prognosticators (CD38, ZAP-70, IGHV gene mutational status) on OS. TTT information and additional laboratory parameters (beta2-M, sCD23) were available for 232/303 patients, whose therapies were established according to NCI-WG criteria. CD49d expression was determined by three-color flow cytometry combining anti-CD49d, anti-CD19 and anti-CD5 mAbs; its expression was demonstrated to be stable over-time and the 30% of positive CD5+CD19+CLL cells was chosen as cut-off to discriminate CD49dlow from CD49dhigh cases. CD49d, whose expression was strongly associated with that of CD38 (p=2.2×10exp-16) and ZAP-70 (p=2.6×10exp-5), or with IGHV gene status (p=1.1×10exp-6), was independent predictor for OS (HR=4.39; p=0.0081) along with IGHV status (HR=5.54; p=0.0005) or, if this parameter was omitted, with ZAP-70 (HR=2.90; p=0.0092). CD49d also effectively predicted TTT and refined the prognostic relevance of all the investigated prognosticators. Notably, a CD49dhigh phenotype, while not changing the outcome of good prognosis (ZAP-70low, mutated-IGHV) CLL, was necessary to correctly predict the bad clinical courses of ZAP-70high (HR=3.12; p=0.023) or unmutated-IGHV (HR=2.95; p=0.002) cases. These findings support the introduction of CD49d detection in routine prognostic assessment of CLL patients, and suggest both pathogenetic and therapeutic implications for CD49d expression in CLL, e.g. envisioning the use of a humanized anti-CD49d monoclonal antibody, currently employed in multiple sclerosis (Natalizumab), for selcted CLL patients.
25. Rituximab Maintenance Following Chemoimmunotherapy Improves Outcome in B-Cell Chronic Lymphocytic Leukemia
- Author
-
Paolo de Fabritiis, Dario Ragusa, Valter Gattei, Sergio Amadori, Pietro Bulian, Francesca Rossi, Luca Maurillo, Adriano Venditti, Maria Ilaria Del Principe, Francesco Buccisano, Giovanni Del Poeta, Laura Giannì, Fabrizio Luciano, and Licia Ottaviani
- Subjects
medicine.medical_specialty ,business.industry ,Chronic lymphocytic leukemia ,Immunology ,Purine analogue ,Cell Biology ,Hematology ,Neutropenia ,medicine.disease ,Biochemistry ,Gastroenterology ,Minimal residual disease ,Fludarabine ,Maintenance therapy ,Chemoimmunotherapy ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Rituximab ,business ,medicine.drug - Abstract
Abstract 2364 Poster Board II-341 The treatment goal of B-cell chronic lymphocytic leukemia (B-CLL) has already shifted from symptom palliation to the attainment of maximal disease control combining purine analogs with monoclonal antibodies. This immunochemotherapeutic approach resulted both in more complete responses (CR) and longer response duration, often remaining only a minimal residual disease (MRD) detectable by flow cytometry. We treated in first line 120 B-CLL symptomatic patients (pts), median age 62 years, with six monthly courses of intravenous or oral fludarabine at conventional doses and then, after a median time of 31 days, with four weekly doses (375 mg/sqm) of rituximab (rtx). Fourteen pts had a low Rai stage, 103 an intermediate stage and 3 a high stage. We defined as high risk pts having at least two of these markers: unmutated IgVH, CD38>30%, ZAP-70>20%, intermediate unfavorable cytogenetics (trisomy 12 or del11q or del17p). Based on NCI criteria, 92/120 (77%) pts achieved a CR, 24/120 (20%) a partial remission (PR) and 4/120 (3%) no response or progression. Ten pts underwent grade 3 (WHO) infective lung toxicity, 1 patient acute fatal B hepatitis and 2 pts progressed towards Richter's syndrome. Hematologic toxicity included mainly neutropenia (grade 3 and/or 4 in 56 pts) and thrombocytopenia (grade 3 and/or 4 in 8 pts). Fifty-four pts either in CR with B-CLL bone marrow cells >1% (MRD+, n=16 pts) or in CR MRD negative, but with B-CLL peripheral cells going up >1000/microl within 1 year after induction (n=22 pts) or in PR (n=16 pts), underwent consolidation and maintenance therapy with four monthly cycles of rtx at 375 mg/sqm followed by twelve monthly low doses of rtx (150 mg/sqm). The median follow-up duration was 50 months. All treated pts experienced a long progression-free survival from the end of induction treatment (40% at 9 years). On the other hand, global overall survival (OS) was 54% at 10 years. Nevertheless, CLL pts undergoing consolidation and maintenance therapy (n=54) showed a longer response duration vs MRD+ not consolidated pts (n=16; 75% vs 9% at 4 years; P1 year) pts (n=43) showed a very long response duration (79% at 6 years, Figure). Moreover, OS was shorter in MRD+ not consolidated pts (0% vs 79% at 15 years; P=0.0007). Noteworthy, within the high risk subset (n=48), consolidated pts (n=17) showed a longer response duration (56% vs 0% at 2.5 years, P=0.003) vs MRD+ not consolidated pts (n=11). Therefore, rituximab consolidation and maintenance immunotherapy improve response duration in B-CLL, thus potentially increasing OS, also within the high risk subset. Disclosures: No relevant conflicts of interest to declare.
26. Chronic Lymphocytic Leukemia Subset Expressing Mutated IGHV3-23 Has Peculiar Clinical and Biological Features
- Author
-
Francesco Bertoni, Elisa Sozzi, Gianluca Gaidano, Michele Dal-Bo, Ilaria Cattarossi, Antonella Zucchetto, Dania Benedetti, Daniela Marconi, Giovanni Del Poeta, Francesca Rossi, Fabrizio Luciano, Rossana Maffei, Pietro Bulian, Roberto Marasca, Francesco Forconi, Milena S. Nicoloso, Luca Laurenti, Riccardo Bomben, Emanuele Zucca, Davide Rossi, Dimitar G. Efremov, Valter Gattei, Maria Ilaria Del Principe, Massimo Degan, and Daniela Capello
- Subjects
Chronic lymphocytic leukemia ,Immunology ,B-cell receptor ,breakpoint cluster region ,Cell Biology ,Hematology ,Biology ,CD38 ,Immunoglobulin light chain ,medicine.disease ,Biochemistry ,Gene expression profiling ,hemic and lymphatic diseases ,medicine ,Immunoglobulin heavy chain ,IGHV@ - Abstract
Abstract 1256 Poster Board I-278 Introduction In the last years, the B cell receptor (BCR) has become a key molecule in chronic lymphocytic leukemia (CLL), given the correlation between mutational status of immunoglobulin heavy chain variable (IGHV) genes and disease prognosis. Recently, a fraction of CLL has been shown to preferentially express specific IGHV genes, often in a non-random combination with homologous heavy chain complementarity-determining region-3 (HCDR3) and peculiar light chains. Some of these stereotyped BCR mark CLL subsets with peculiar clinical behavior regardless of IGHV mutations. These data suggest a role for BCR in defining the clinical and biological features of CLL, also beyond the mutational status of IGHV genes. Patients and Methods A HCDR3-driven clustering of 1,426 IG sequences (1,398 patients) was performed using ClustalX(1.83). Time to treatment (TTT) intervals, Rai staging, IGHV mutational status, CD38, ZAP-70, and karyotype abnormalities evaluated by FISH were available for 617 patients. Gene expression profiling (GEP) and quantitative real-time PCR experiments (QRT-PCR) were performed on purified CLL cells. Results IGHV3-23 was totally absent in 71 identified stereotyped clusters despite being the second most frequently used IGHV gene, such distribution was significantly skewed (p Conclusion Expression of IGHV3-23 marks a subset of M CLL with a worse prognosis; such a peculiar clinical behavior may be related to superantigen stimulation combined with down-regulation of specific growth/tumor suppressor genes and up-regulation of miR-15a and miR-16-1. Disclosures No relevant conflicts of interest to declare.
27. ZAP-70 Expression Evaluated by Mean Fluorescence Intensity T/B Ratio Is a More Useful Prognosticator Than Percentage of Positive Cells in Chronic Lymphocytic Leukemia (CLL)
- Author
-
Davide Rossi, Valter Gattei, Gianluca Gaidano, Giovanni Del Poeta, Michele Dal-Bo, Massimo Degan, Fabrizio Luciano, Dania Benedetti, Antonella Zucchetto, Riccardo Bomben, Francesca Rossi, Pietro Bulian, Maria Irno Consalvo, and Maria Ilaria Del Principe
- Subjects
Oncology ,medicine.medical_specialty ,Univariate analysis ,Pathology ,Multivariate analysis ,business.industry ,Chronic lymphocytic leukemia ,Immunology ,Hazard ratio ,Cell Biology ,Hematology ,CD38 ,medicine.disease ,Biochemistry ,Internal medicine ,Cohort ,medicine ,Stage (cooking) ,business ,IGHV@ - Abstract
Abstract 1257 Poster Board I-279 Introduction Expression of the T-cells constitutive ZAP-70 protein by CLL cells has been the focus of many studies in the last few years, due to its ability to stratify indolent and more aggressive disease subsets. Although the strength of ZAP-70 as independent negative prognosticator was demonstrated by several studies, concerns about its use derive from a lack of multicentric standardization of flow-cytometric protocols. Analyses in clinical settings are usually performed according to two methods, respectively evaluating the percentage of CLL cells expressing ZAP-70 compared to isotypic control (ISO-method), or to autologous T-cells (T-method). Of note, while the two methods yield concordant results in most patients, a fraction of cases may be discordant as for evaluation of ZAP-70 positivity. Moreover, either method suffers of an operator dependent variability, mainly related to subjectivity in cursor placement to determine the percentage of ZAP-70+ cells. The aim of this study was to compare the ISO- and T-methods with the expression of ZAP-70 evaluated as Mean-Fluorescence-Intensity (MFI) Ratio between gated T and CLL cells (T/B-Ratio-method), and to assess the prognostic significance of the three approaches. Methods Cytometric files relative to ZAP-70 determination according to the three readouts were retrospectively reviewed with BD-DiVa software on a cohort of 173 patients (test set), all with complete clinical and biological prognostic assessment and time-to-treatment (TTT) available. Findings were then validated in an independent cohort of 341 cases from a different institution (validation set). Notably, in the two cohorts, ZAP-70 assessment was accomplished using two different antibody combinations and instrumentations for data acquisition and analysis. Results ZAP-70 expression was reviewed in the test set by applying the ISO- and T-methods. Utilizing respectively 11% for ISO-method and 20% of ZAP-70+ cells for T-method, both selected as optimal cut-offs with prognostic relevance by ROC-analysis and maximally selected log-rank statistics, 66 (ISO-method) and 60 (T-method) ZAP-70+ cases were defined. By applying the T/B-Ratio-method, a value of 3.0 was identified as the optimal prognostic cut-point. According to this value, 73 ZAP-70+ cases (i.e. with T/B-Ratio Conclusions We suggest to evaluate ZAP-70 expression in routine settings using the T/B-Ratio-method, given the operator and laboratory independent feature of this approach. We propose the 3.0 T/B-Ratio value as optimal cut-off to discriminate ZAP-70+ (T/B-Ratio less than 3.0) from ZAP-70− (T/B-Ratio more/equal than 3.0) cases Disclosures No relevant conflicts of interest to declare.
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.